The Use of Patient‐Reported Outcome Measures in the Evaluation of Medical Products for Regulatory Approval | Zendy

Burke LB | Zendy; Kennedy DL | Zendy; Miskala PH | Zendy; Papadopoulos EJ | Zendy; Trentacosti AM | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

The Use of Patient‐Reported Outcome Measures in the Evaluation of Medical Products for Regulatory Approval

Author(s) -

Burke LB,

Kennedy DL,

Miskala PH,

Papadopoulos EJ,

Trentacosti AM

Publication year - 2008

Publication title -

clinical pharmacology and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.941

H-Index - 188

eISSN - 1532-6535

pISSN - 0009-9236

DOI - 10.1038/clpt.2008.128

Subject(s) - clinical pharmacology , outcome (game theory) , perspective (graphical) , medicine , function (biology) , clinical trial , alternative medicine , psychology , intensive care medicine , family medicine , pharmacology , computer science , pathology , mathematics , mathematical economics , artificial intelligence , evolutionary biology , biology

Patient‐reported outcome (PRO) measures provide an important perspective on how patients feel and function that cannot be adequately captured by clinical measures. A PRO is any report that comes directly from a patient about a health condition or its treatment without interpretation of the patient's response by a clinician or anyone else. Clinical Pharmacology & Therapeutics (2008); 84 , 2, 281–283 doi: 10.1038/clpt.2008.128

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research